CCI
KALA icon

Columbus Circle Investors’s KALA BIO KALA Stock Holding History

Columbus Circle Investors’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-22
Closed -$419K – 161
2020
Q3 		$419K Sell
22
-4
-15% -$91.9K 0.02% 159
2020
Q2 		$670K Buy
+26
New +$736K 0.03% 144

Other funds holding KALA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Columbus Circle Investors's KALA Position: Q4 2020 in Review

Columbus Circle Investors sold out of KALA BIO (KALA) in Q4 2020, closing a stake of 22 shares — an estimated $419K sold.

Columbus Circle Investors first reported a position in KALA in Q2 2020 and held it in 2 quarters. The position peaked at $670K in Q2 2020. 112 funds tracked by Wall St. Rank hold KALA as of Q4 2020.

  • Columbus Circle Investors reported no remaining KALA BIO position as of Q4 2020 after selling out during the quarter.
  • Columbus Circle Investors sold 22 KALA BIO shares in Q4 2020, an estimated $419K.
  • Columbus Circle Investors first reported a position in KALA BIO in Q2 2020 and held it in 2 quarters.
  • Columbus Circle Investors's KALA BIO position peaked at $670K in Q2 2020.
  • 112 funds tracked by Wall St. Rank held KALA BIO as of Q4 2020.

Based on Columbus Circle Investors's 13F filing for Q4 2020, filed 20 Jan 2021.